Skip to main content
AAPL+0.73%NVDA-4.90%MSFT+1.47%GOOGL+1.96%AMZN+1.71%TSM-0.77%SPCX+2.65%AVGO+6.31%META-0.31%TSLA+0.32%LLY+0.64%BRK-B+0.82%SKHY-2.54%WMT+0.23%MU-2.31%JPM+0.61%AMD+6.38%V+0.24%XOM+1.06%JNJ+1.20%ASMLa-1.67%MA-0.02%ABBV+0.61%COST+0.74%1398.HK-0.63%0700.HK-2.64%KO+0.34%CVX+1.09%CSCO+0.88%PG+0.51%ORCL0.00%UNH+0.24%GE-1.25%0939.HK-0.57%HD-0.03%BAC+0.31%3988.HK+0.32%INTC-0.25%1816.HK+0.65%0857.HK-0.50%AMAT+0.02%0005.HK-0.64%AP2d-0.54%HSBA.L-0.18%PM+1.52%1288.HK-0.73%NVS+0.37%MS+0.46%LRCX+1.12%AZN-0.43%NZDCHF+1.76%USDCHF+1.73%USDZAR+1.10%USDTHB+1.01%NZDJPY+0.96%EURCHF+0.95%NZDCAD+0.94%USDCAD+0.93%USDJPY+0.93%GBPNZD-0.91%AUDCHF+0.88%GBPUSD-0.88%AUDNZD-0.87%AUDUSD-0.84%EURZAR+0.81%CADCHF+0.81%GBPCHF+0.81%CHFJPY-0.80%EURNZD-0.80%GBPZAR+0.80%EURUSD-0.78%USDSEK+0.48%GBPTRY+0.41%AUDSGD-0.37%AUDNOK-0.35%GBPHKD+0.32%EURCNH-0.30%EURHKD-0.30%CHFSEK+0.29%USDDKK+0.29%GBPMXN-0.28%AUDDKK-0.27%USDTRY+0.25%EURPLN-0.22%USDNOK+0.21%NZDMXN-0.21%USDSGD+0.20%EURSEK+0.19%USDILS+0.16%EURCAD+0.15%EURJPY+0.15%EURGBP+0.13%NOKJPY-0.12%GBPSGD-0.10%SGDJPY-0.10%EURSGD-0.09%AUDJPY+0.09%USDMXN+0.08%AUDCAD+0.08%EURNOK-0.08%USDPLN+0.08%NZDUSD+0.07%EURAUD+0.07%NZDSGD-0.07%USDHKD+0.07%GBPAUD-0.05%USDCOP-0.04%CHFNOK+0.03%GBPJPY+0.02%EURCZK+0.02%GBPCAD+0.02%PLNJPY+0.02%CHFSGD+0.01%USDCNH+0.01%CADJPY0.00%EURDKK0.00%COFFEE+3.13%GAGUSD-2.99%XAGUSD-2.99%XAUUSD-2.86%GAUUSD-2.86%SUGAR-1.52%XNGUSD+1.39%HG1-1.28%W1-1.05%UKOIL+0.90%XPTUSD-0.80%S1-0.45%BTCUSD-2.85%ETHUSD+40.05%USDTUSD+0.01%XRPUSD+42.66%SOLUSD+42.29%TRXUSDT-0.13%ZECUSDT+0.42%DOGEUSD+38.92%XMRUSDT-3.81%LINKUSD-1.72%XLMUSD-1.47%BCHUSDT-1.40%UNIUSD-2.21%LTCUSD+34.13%TONUSD+46.15%SUIUSD-2.53%HBARUSDT-2.81%TAOUSDT-2.73%AAVEUSD-5.31%ICPUSDT-0.69%DOTUSDT-1.06%ONDOUSDT-2.20%ARBUSDT-2.67%JUPUSDT+2.55%WLDUSDT-0.14%INJUSDT-0.21%ATOMUSDT+1.56%STXUSDT-4.58%PYTHUSDT+1.15%TIAUSDT+1.42%FETUSDT-1.39%SEIUSDT-2.79%IMXUSDT-2.06%OPUSDT-2.94%GRTUSDT-2.27%POLUSDT-2.32%WIFUSDT-1.55%IOTAUSDT+1.11%AXSUSDT-1.61%EOSUSDT-1.60%FARTCOINUSDT-2.67%DYDXUSDT-1.18%GALAUSDT-0.54%ORDIUSDT-0.91%NOTUSDT+1.27%RONINUSDT-7.68%AAPL+0.73%NVDA-4.90%MSFT+1.47%GOOGL+1.96%AMZN+1.71%TSM-0.77%SPCX+2.65%AVGO+6.31%META-0.31%TSLA+0.32%LLY+0.64%BRK-B+0.82%SKHY-2.54%WMT+0.23%MU-2.31%JPM+0.61%AMD+6.38%V+0.24%XOM+1.06%JNJ+1.20%ASMLa-1.67%MA-0.02%ABBV+0.61%COST+0.74%1398.HK-0.63%0700.HK-2.64%KO+0.34%CVX+1.09%CSCO+0.88%PG+0.51%ORCL0.00%UNH+0.24%GE-1.25%0939.HK-0.57%HD-0.03%BAC+0.31%3988.HK+0.32%INTC-0.25%1816.HK+0.65%0857.HK-0.50%AMAT+0.02%0005.HK-0.64%AP2d-0.54%HSBA.L-0.18%PM+1.52%1288.HK-0.73%NVS+0.37%MS+0.46%LRCX+1.12%AZN-0.43%NZDCHF+1.76%USDCHF+1.73%USDZAR+1.10%USDTHB+1.01%NZDJPY+0.96%EURCHF+0.95%NZDCAD+0.94%USDCAD+0.93%USDJPY+0.93%GBPNZD-0.91%AUDCHF+0.88%GBPUSD-0.88%AUDNZD-0.87%AUDUSD-0.84%EURZAR+0.81%CADCHF+0.81%GBPCHF+0.81%CHFJPY-0.80%EURNZD-0.80%GBPZAR+0.80%EURUSD-0.78%USDSEK+0.48%GBPTRY+0.41%AUDSGD-0.37%AUDNOK-0.35%GBPHKD+0.32%EURCNH-0.30%EURHKD-0.30%CHFSEK+0.29%USDDKK+0.29%GBPMXN-0.28%AUDDKK-0.27%USDTRY+0.25%EURPLN-0.22%USDNOK+0.21%NZDMXN-0.21%USDSGD+0.20%EURSEK+0.19%USDILS+0.16%EURCAD+0.15%EURJPY+0.15%EURGBP+0.13%NOKJPY-0.12%GBPSGD-0.10%SGDJPY-0.10%EURSGD-0.09%AUDJPY+0.09%USDMXN+0.08%AUDCAD+0.08%EURNOK-0.08%USDPLN+0.08%NZDUSD+0.07%EURAUD+0.07%NZDSGD-0.07%USDHKD+0.07%GBPAUD-0.05%USDCOP-0.04%CHFNOK+0.03%GBPJPY+0.02%EURCZK+0.02%GBPCAD+0.02%PLNJPY+0.02%CHFSGD+0.01%USDCNH+0.01%CADJPY0.00%EURDKK0.00%COFFEE+3.13%GAGUSD-2.99%XAGUSD-2.99%XAUUSD-2.86%GAUUSD-2.86%SUGAR-1.52%XNGUSD+1.39%HG1-1.28%W1-1.05%UKOIL+0.90%XPTUSD-0.80%S1-0.45%BTCUSD-2.85%ETHUSD+40.05%USDTUSD+0.01%XRPUSD+42.66%SOLUSD+42.29%TRXUSDT-0.13%ZECUSDT+0.42%DOGEUSD+38.92%XMRUSDT-3.81%LINKUSD-1.72%XLMUSD-1.47%BCHUSDT-1.40%UNIUSD-2.21%LTCUSD+34.13%TONUSD+46.15%SUIUSD-2.53%HBARUSDT-2.81%TAOUSDT-2.73%AAVEUSD-5.31%ICPUSDT-0.69%DOTUSDT-1.06%ONDOUSDT-2.20%ARBUSDT-2.67%JUPUSDT+2.55%WLDUSDT-0.14%INJUSDT-0.21%ATOMUSDT+1.56%STXUSDT-4.58%PYTHUSDT+1.15%TIAUSDT+1.42%FETUSDT-1.39%SEIUSDT-2.79%IMXUSDT-2.06%OPUSDT-2.94%GRTUSDT-2.27%POLUSDT-2.32%WIFUSDT-1.55%IOTAUSDT+1.11%AXSUSDT-1.61%EOSUSDT-1.60%FARTCOINUSDT-2.67%DYDXUSDT-1.18%GALAUSDT-0.54%ORDIUSDT-0.91%NOTUSDT+1.27%RONINUSDT-7.68%
BT

Beam Therapeutics Inc. (BEAM)

NASDAQ • Healthcare

$25.81
+$0.66 (+2.6%)
Market open

Last close at November 11, 2026 at 21:00 UTC

Open$25.47
Previous Close$25.81
Day Range$24.68 - $26.06
Avg. Volume (3M)1.8M
Market Cap$2.6B
52 Week Range
$20.23$38.26

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$307K100%
Gross Profitminus cost of goods$307K100%

Fundamentals & Financials

Revenue (TTM)
$146.6M
Net Income (TTM)
-$107.1M
EPS (TTM)
-$1
ROA (TTM)
-8.44%
Current Ratio
13

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-4.6%Q2 2026-$0.91
-6.3%Q3 2026-$1.18
-11.3%Q4 2026-$1.28

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -11.3%

Beam Therapeutics’ EPS trailed consensus in the third fiscal quarter of 2026, reported November 3, 2026, with EPS of -$1.28 trailing the -$1.15 estimate by -$0.13 and deteriorating from -$1.10 a year ago (a -16.4% year-over-year change). The quarter’s net loss widened as net income fell 19.2% year over year to roughly -$134.4 million (down from -$112.7 million a year ago), alongside an operating loss of about -$141.3 million, as the company continued investing across its gene-editing pipeline programs including BEAM-101, BEAM-102, BEAM-201, and BEAM-301. Cash generation remained negative, with negative operating cash flow of around -$110.7 million. For the next period, consensus calls for EPS of -$1.25 on revenue of $7.9 million.

View full earnings history

About Beam Therapeutics Inc.

Beam Therapeutics Inc. develops gene-editing medicines in biotechnology, focused on precise genetic remedies for severe diseases. The company, which trades on NASDAQ as BEAM, recorded $139.7 million in revenue in FY2025. Its work centers on engineered therapies for blood disorders and other serious conditions, with operations based in the United States.

Name
Beam Therapeutics Inc.
CEO
John Evans
Industry
Healthcare
Year Founded
2017
Employees
540

Today's Snapshot

AI-generated

BEAM opened 2.9% lower at 25.05, while its sector was flat. Beam Therapeutics reported success in a late-stage sickle-cell trial.

Trading Volume

Below 10d avg (1.7M)

227.2K

vs S&P 500 Today

Strong Underperformance

-4.33%

Updated: November 12, 2026 at 15:37 UTC

Technical Indicators

0 Buy3 Neutral5 Sell
Beam exhibits a bearish technical tilt as the market price sits below most moving averages and beneath the classic pivot, indicating prevailing resistance. Momentum is negative and MACD is tepid, while the ADX points to a weak trend rather than a strong directional move. Volatility is elevated relative to price, reflected in a higher ATR percentage, and on-balance volume diverges by showing some accumulation even as price remains depressed. Technical takeaway: Sell, characterized by price below key averages and higher-than-normal volatility with limited trend strength.
All signals
  • EMA (5 indicators)$25.81 - $27.17
    Sell
  • RSI (14)45.81
    Neutral
  • Stochastic %K (14, 3, 3)29.71
    Neutral
  • MACD Level (12, 26)0.14
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.